L

Lord Johnson of Lainston (Con)

Speaking in the House of Lords on 11 September 2025

Debate

Merck Research Site

Contribution

I am sorry, but I was actually in the doorway, coming in. I would be grateful if I could ask the question, if that is possible. My noble friend Lord Markham raised an important point about the Treasury’s view of how these pricing processes function. The reality is that if we do not have the drug companies in this country, we are not just going to miss the opportunity for investment, we will lose the opportunity for clinical trials for our patients and individuals in the NHS to get access to these new medicines. I return to the question about an assessment of the overall cost of these measures and a proper assessment of the understanding of how investment from the biopharma sector in the UK actually adds up, not just in relation to the pounds, shillings and pence of the medicines.

More from Lord Johnson of Lainston (Con)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

Partner sites